Date published: 2025-9-11

00800 4573 8000

SCBT Portrait Logo
Seach Input

Inhibiteurs SLC17A (solute carrier family 17)

The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.

Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.

VOIR ÉGALEMENT...

Items  1  to  10  of  23 total

Afficher:

Nom du produitCAS #Ref. CatalogueQuantitéPrix HTCITATIONS Classement

6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione

118876-58-7sc-478080
5 mg
$70.00
1
(0)

Le NBQX est un antagoniste des récepteurs AMPA, qui peut indirectement affecter la signalisation et la libération du glutamate.

D(−)-2-Amino-5-phosphonovaleric acid (D-AP5)

79055-68-8sc-200434
5 mg
$95.00
2
(1)

En tant qu'antagoniste des récepteurs NMDA, l'AP5 peut influencer indirectement la signalisation et la libération du glutamate.

6-Cyano-7-nitroquinoxaline-2,3-dione

115066-14-3sc-505104
10 mg
$204.00
2
(0)

Le CNQX est un antagoniste puissant des récepteurs AMPA, qui affecte indirectement la signalisation et la libération du glutamate.

Kynurenic acid

492-27-3sc-202683
sc-202683A
sc-202683B
250 mg
1 g
5 g
$25.00
$56.00
$135.00
6
(1)

Il s'agit d'un antagoniste à large spectre des récepteurs des acides aminés excitateurs, qui réduit la signalisation du glutamate.

Riluzole

1744-22-5sc-201081
sc-201081A
sc-201081B
sc-201081C
20 mg
100 mg
1 g
25 g
$20.00
$189.00
$209.00
$311.00
1
(1)

Le riluzole inhibe la libération de glutamate, influençant indirectement la fonction de SLC17A7.

Memantine hydrochloride

41100-52-1sc-203628
50 mg
$68.00
4
(2)

Il s'agit d'un antagoniste des récepteurs NMDA, qui affecte indirectement la signalisation du glutamate.

Ethosuximide

77-67-8sc-211431
1 g
$300.00
(0)

Ce composé réduit l'activité des canaux calciques de type T, ce qui peut indirectement influencer la libération de glutamate.

Lamotrigine

84057-84-1sc-201079
sc-201079A
10 mg
50 mg
$118.00
$476.00
1
(1)

La lamotrigine inhibe les canaux sodiques sensibles au voltage, ce qui entraîne une diminution de la libération de glutamate.

Topiramate

97240-79-4sc-204350
sc-204350A
10 mg
50 mg
$105.00
$362.00
(1)

Il module les courants évoqués par le GABA, influençant indirectement la libération de glutamate.

Felbamate

25451-15-4sc-203579
sc-203579A
10 mg
50 mg
$101.00
$373.00
(0)

Le felbamate agit comme un antagoniste des récepteurs NMDA, affectant indirectement la signalisation et la libération du glutamate.